Inhibition of endothelial SCUBE2 (signal peptide-CUB-EGF domain-containing protein 2), a Novel VEGFR2 (vascular endothelial growth factor receptor 2) coreceptor, suppresses tumor angiogenesis

Yuh Charn Lin, Chun Yu Liu, Reiji Kannagi, Ruey Bing Yang

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Objective—SCUBE2 (signal peptide-CUB-EGF domain-containing protein 2), expressed on the endothelial cell surface, functions as a novel coreceptor for VEGFR2 (vascular endothelial growth factor receptor 2) and enhances VEGF-induced signaling in adult angiogenesis. However, whether SCUBE2 plays a role in pathological angiogenesis and whether anti-SCUBE2 antibody is an effective strategy for blocking tumor angiogenesis remain unknown. The aim of this study was to investigate the pathological role and targeting therapy of SCUBE2 in tumor vasculature. Approach and Results—Immunohistochemistry revealed that SCUBE2 is highly expressed in endothelial cells of numerous carcinomas. Genetic endothelial cell knockout of SCUBE2 and pharmacological inhibition with the anti-SCUBE2 monoclonal antibody SP.B1 significantly reduced xenograft tumor growth, decreased tumor vascular density, increased apoptosis, and decreased the proliferation of tumor cells. Mechanistic studies revealed that SP.B1 binds to SCUBE2 and induces its internalization for lysosomal degradation, thereby reducing its cell surface level and inhibiting the binding of and downstream signaling of VEGF, including VEGFR2 phosphorylation and AKT/MAPK (mitogen-activated protein kinase) activation. Importantly, dual combination therapy with anti-SCUBE2 monoclonal antibody and anti-VEGF antibody or chemotherapy was more effective than single-agent therapy. Conclusions—Endothelial cell surface SCUBE2 is a VEGFR2 coreceptor essential for pathological tumor angiogenesis, and anti-SCUBE2 monoclonal antibody acting as an internalization inducer may provide a potent combination therapy for tumor angiogenesis.

Original languageEnglish
Pages (from-to)1202-1215
Number of pages14
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume38
Issue number5
DOIs
Publication statusPublished - 2018

Keywords

  • Antibody therapy
  • Endothelial cell
  • SCUBE2
  • Tumor angiogenesis
  • VEGFR2

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Inhibition of endothelial SCUBE2 (signal peptide-CUB-EGF domain-containing protein 2), a Novel VEGFR2 (vascular endothelial growth factor receptor 2) coreceptor, suppresses tumor angiogenesis'. Together they form a unique fingerprint.

Cite this